Medical devices to treat or inhibit restenosis
First Claim
1. An implantable medical device for the treatment or inhibition of restenosis coated with a PKC inhibitor selected from the group consisting of ruboxistaurin, and pharmaceutically acceptable derivatives thereof.
1 Assignment
0 Petitions
Accused Products
Abstract
Implantable medical devices having anti-restenotic coatings are disclosed. Specifically, implantable medical devices having coatings of certain antiproliferative agents, particularly a certain PKC inhibitor, are disclosed. The anti-restenotic PKC inhibitor is ruboxistaurin, and pharmaceutically acceptable derivatives thereof. The anti-restenotic medical devices include stents, catheters, micro-particles, probes and vascular grafts. Intravascular stents are preferred medical devices. The medical devices can be coated using any method known in the art including compounding the PKC inhibitor with a biocompatible polymer prior to applying the coating. Moreover, medical devices composed entirely of biocompatible polymer-PKC inhibitor blends are disclosed. Additionally, medical devices having a coating comprising at least one PKC inhibitor in combination with at least one additional therapeutic agent are also disclosed. Furthermore, related methods of using and making the anti-restenotic implantable devices are also disclosed.
101 Citations
14 Claims
- 1. An implantable medical device for the treatment or inhibition of restenosis coated with a PKC inhibitor selected from the group consisting of ruboxistaurin, and pharmaceutically acceptable derivatives thereof.
- 5. An intravascular stent for site-specific, controlled-release delivery of a medicament for the treatment or inhibition of restenosis, said stent having a coating comprising a biocompatible polymer and a PKC inhibitor selected from the group consisting of ruboxistaurin and pharmaceutically acceptable derivatives thereof.
-
9. A method of treating or inhibiting restenosis comprising:
-
providing an intravascular stent having a coating comprising a PKC inhibitor selected from the group consisting of ruboxistaurin and pharmaceutically acceptable derivatives thereof; and
implanting said intravascular stent into a blood vessel lumen at risk for restenosis wherein said PKC inhibitor is released into tissue adjacent said blood vessel lumen in a controlled release manner. - View Dependent Claims (10)
-
-
11. A method for producing a medical device comprising:
-
providing medical device to be coated;
compounding ruboxistaurin or a pharmaceutically acceptable derivative thereof with a carrier compound; and
coating said medical device with said ruboxistaurin or pharmaceutically acceptable derivative thereof compounded with said carrier compound. - View Dependent Claims (12, 13, 14)
-
Specification